TABLE 3.
Indications for Rituximab
| Indication | Counts, n (%) |
|---|---|
| Approved indications | 1,111 (66.4) |
| Autoimmunea | 163 (14.7) |
| Chronic lymphocytic leukemia | 84 (7.6) |
| Non-Hodgkin lymphoma | 738 (66.4) |
| Rheumatologic disease | 126 (11.3) |
| Off-label indications | 563 (34.6) |
| Autoimmune | 26 (4.6) |
| End organ manifestation | 22 (3.9) |
| Hematologic | 41 (7.3) |
| Neurologicb | 409 (72.7) |
| Oncologic | 11 (2.0) |
| Transplant | 16 (2.8) |
| Vascular/dermatologic | 23 (4.1) |
| Other | 15 (2.7) |
aIncludes Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, immune thrombocytopenic purpura, and pemphigus vulgaris.
b374 (91.4%) were for demyelinating diseases (including demyelinating neuropathies, demyelinating central nervous system diseases, and multiple sclerosis), and 35 (8.6%) were for neurologic disorders (including cerebral ataxia, encephalitis, encephalomyelitis, myasthenia gravis, myoneural disorders, neuropathies, and stiff-person syndrome).